CGEN
Price
$1.26
Change
-$0.03 (-2.33%)
Updated
May 9 closing price
Capitalization
118.87M
82 days until earnings call
CYCN
Price
$3.28
Change
+$0.12 (+3.80%)
Updated
May 9 closing price
Capitalization
10.03M
Ad is loading...

CGEN vs CYCN

Header iconCGEN vs CYCN Comparison
Open Charts CGEN vs CYCNBanner chart's image
Compugen
Price$1.26
Change-$0.03 (-2.33%)
Volume$114.99K
Capitalization118.87M
Cyclerion Therapeutics
Price$3.28
Change+$0.12 (+3.80%)
Volume$40.44K
Capitalization10.03M
CGEN vs CYCN Comparison Chart
Loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGEN vs. CYCN commentary
May 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a Hold and CYCN is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 10, 2025
Stock price -- (CGEN: $1.26 vs. CYCN: $3.28)
Brand notoriety: CGEN and CYCN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 46% vs. CYCN: 179%
Market capitalization -- CGEN: $118.87M vs. CYCN: $10.03M
CGEN [@Biotechnology] is valued at $118.87M. CYCN’s [@Biotechnology] market capitalization is $10.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 1 FA rating(s) are green whileCYCN’s FA Score has 1 green FA rating(s).

  • CGEN’s FA Score: 1 green, 4 red.
  • CYCN’s FA Score: 1 green, 4 red.
According to our system of comparison, CYCN is a better buy in the long-term than CGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 5 TA indicator(s) are bullish while CYCN’s TA Score has 6 bullish TA indicator(s).

  • CGEN’s TA Score: 5 bullish, 5 bearish.
  • CYCN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CYCN is a better buy in the short-term than CGEN.

Price Growth

CGEN (@Biotechnology) experienced а -14.86% price change this week, while CYCN (@Biotechnology) price change was +4.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.25%. For the same industry, the average monthly price growth was +9.40%, and the average quarterly price growth was -13.49%.

Reported Earning Dates

CGEN is expected to report earnings on Jul 31, 2025.

CYCN is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-6.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGEN($119M) has a higher market cap than CYCN($10M). CYCN YTD gains are higher at: 1.814 vs. CGEN (-17.647). CYCN has higher annual earnings (EBITDA): -3.63M vs. CGEN (-14.41M). CGEN has more cash in the bank: 103M vs. CYCN (3.23M). CYCN has less debt than CGEN: CYCN (0) vs CGEN (2.91M). CGEN has higher revenues than CYCN: CGEN (27.9M) vs CYCN (2M).
CGENCYCNCGEN / CYCN
Capitalization119M10M1,190%
EBITDA-14.41M-3.63M397%
Gain YTD-17.6471.814-973%
P/E Ratio60.33N/A-
Revenue27.9M2M1,395%
Total Cash103M3.23M3,187%
Total Debt2.91M0-
FUNDAMENTALS RATINGS
CGEN vs CYCN: Fundamental Ratings
CGEN
CYCN
OUTLOOK RATING
1..100
6185
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
6445
P/E GROWTH RATING
1..100
24100
SEASONALITY SCORE
1..100
2750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYCN's Valuation (23) in the null industry is somewhat better than the same rating for CGEN (78) in the Biotechnology industry. This means that CYCN’s stock grew somewhat faster than CGEN’s over the last 12 months.

CYCN's Profit vs Risk Rating (100) in the null industry is in the same range as CGEN (100) in the Biotechnology industry. This means that CYCN’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's SMR Rating (95) in the Biotechnology industry is in the same range as CYCN (96) in the null industry. This means that CGEN’s stock grew similarly to CYCN’s over the last 12 months.

CYCN's Price Growth Rating (45) in the null industry is in the same range as CGEN (64) in the Biotechnology industry. This means that CYCN’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's P/E Growth Rating (24) in the Biotechnology industry is significantly better than the same rating for CYCN (100) in the null industry. This means that CGEN’s stock grew significantly faster than CYCN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENCYCN
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 24 days ago
82%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA298.2613.44
+4.72%
Tesla
GME27.540.76
+2.84%
GameStop Corp
AAPL198.531.04
+0.53%
Apple
SPY564.34-0.72
-0.13%
SPDR® S&P 500® ETF
BTC.X102970.850000-270.609380
-0.26%
Bitcoin cryptocurrency

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with BDTX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then BDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
-2.33%
BDTX - CGEN
38%
Loosely correlated
-2.96%
ARWR - CGEN
36%
Loosely correlated
-1.66%
ROIV - CGEN
36%
Loosely correlated
-3.54%
RLAY - CGEN
35%
Loosely correlated
N/A
SNDX - CGEN
35%
Loosely correlated
-2.82%
More

CYCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCN has been loosely correlated with BLUE. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCN jumps, then BLUE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCN
1D Price
Change %
CYCN100%
+3.83%
BLUE - CYCN
37%
Loosely correlated
-5.66%
HRTX - CYCN
32%
Poorly correlated
-2.76%
GDTC - CYCN
31%
Poorly correlated
-3.47%
ENTO - CYCN
25%
Poorly correlated
+5.09%
CGEN - CYCN
23%
Poorly correlated
-2.33%
More